Instanyl (fentanyl) multidose nasal sprays discontinued
6th November 2018
Takeda UK is discontinuing all strengths of Instanyl® (fentanyl citrate) multidose nasal sprays on the 14th December 2018 for commercial reasons.
The single dose Instanyl® products (50micorgram/mL, 100microgram/mL and 200micorgram/mL) will remain available.
Alternative transmucosal fentanyl citrate products are available including, sublingual (Abstral®) and buccal (Effentora®) tablets, a lozenge with oromucosal applicator (Actiq®) and a nasal spray (Pecfent®). However, these products are not interchangeable on a microgram per microgram basis from one product to another and patients must undergo full titration if switching to a new product.
See the PCF Fentanyl (transmucosal) monograph and individual SPCs for details.
Recent news
- RPS Wales Palliative and End of Life Care Policy
- NICE guidelines for COPD updated
- AWMSG approves tiotropium
- Palliative Care Formulary migration to MedicinesComplete - January 2019
- Supplementary information on cannabis-based products for medicinal use
- Report on action taken on ambulatory syringe drivers
- NICE consultation on cannabis-based products for medicinal use
- Guidance and information on prescribing and supply of cannabis-based products for medicinal use
- Instanyl (fentanyl) multidose nasal sprays discontinued
- Gabapentin and pregabalin to be controlled as class C drugs
News archive
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000